JP2008514376A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514376A5
JP2008514376A5 JP2007534813A JP2007534813A JP2008514376A5 JP 2008514376 A5 JP2008514376 A5 JP 2008514376A5 JP 2007534813 A JP2007534813 A JP 2007534813A JP 2007534813 A JP2007534813 A JP 2007534813A JP 2008514376 A5 JP2008514376 A5 JP 2008514376A5
Authority
JP
Japan
Prior art keywords
rotigotine
use according
max
parkinson
disease symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007534813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514376A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/035257 external-priority patent/WO2006039532A2/en
Publication of JP2008514376A publication Critical patent/JP2008514376A/ja
Publication of JP2008514376A5 publication Critical patent/JP2008514376A5/ja
Pending legal-status Critical Current

Links

JP2007534813A 2004-09-29 2005-09-29 パーキンソン病のための経皮治療システム Pending JP2008514376A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61376004P 2004-09-29 2004-09-29
US61376104P 2004-09-29 2004-09-29
PCT/US2005/035257 WO2006039532A2 (en) 2004-09-29 2005-09-29 Transdermal therapeutic system for parkinson’s disease

Publications (2)

Publication Number Publication Date
JP2008514376A JP2008514376A (ja) 2008-05-08
JP2008514376A5 true JP2008514376A5 (enExample) 2008-11-13

Family

ID=36143101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007534813A Pending JP2008514376A (ja) 2004-09-29 2005-09-29 パーキンソン病のための経皮治療システム

Country Status (3)

Country Link
EP (1) EP1796610A4 (enExample)
JP (1) JP2008514376A (enExample)
WO (1) WO2006039532A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JPWO2015129527A1 (ja) 2014-02-27 2017-03-30 株式会社 メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6448303B1 (en) * 2000-12-29 2002-09-10 National Starch And Chemical Investment Holding Corporation Hot melt adhesives for dermal application
DK1256339T3 (da) * 2001-05-08 2004-02-09 Sanol Arznei Schwarz Gmbh Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
EP1256340B1 (en) * 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base

Similar Documents

Publication Publication Date Title
Shakya et al. Palatal mucosa as a route for systemic drug delivery: A review
US9675562B2 (en) Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
ES2204780T3 (es) Sistema terapeutico transdermico para la enfermedad de parkinson que induce altos niveles de rotigotina en plasma.
KR20010040785A (ko) 손톱(발톱)진균증의 치료를 위한 압력 민감성접착메트릭스 패치
HUP0302897A2 (hu) Kiváló hatású transzdermális terápiás készítmény a Parkinson-kór kezelésére
TWI343263B (en) Patches for mucosa of oral cavity containing fentanyl
TWI454249B (zh) 用於治療或預防甲癬或足癬之壓敏膠黏劑基質藥貼裝置
WO2001008681A1 (en) Methods of administration of glycopyrrolate compositions
US20220142953A1 (en) Lidocaine patch and methods of use thereof
JP2002531488A5 (enExample)
JP2010500992A (ja) アルツハイマー病の経皮的治療法及び経皮的治療システム
KR20050116365A (ko) 경피성 그라니세트론
IL152573A (en) A system for the transmission through the skin of a medical preparation against vomiting and nausea
Ghaferi et al. Transdermal Drug Delivery Systems (TDDS): recent advances and failure modes
KR101307650B1 (ko) 구역에 대한 경피 방법 및 패치
US9408802B1 (en) Seven day drug in adhesive transdermal delivery
JP2020505322A (ja) 局所用デトミジン製剤
JP2008514376A5 (enExample)
NO20062234L (no) Transdemisk,farmasoytisk spray-formulering omfattende en VP/UA kopolymer og en ikke-vandig vehikkel
Sahu et al. Formulation, characterization and ex vivo evaluation of epinephrine transdermal patches
NO320050B1 (no) Transmukosale formuleringer av levosimendan og anvendelse derav til fremstilling av faramasoytisk preparat.
KR101267771B1 (ko) 약제 조합을 이용한 치료 방법 및 이에 적합한 약제 조합
JP2010514789A (ja) 副腎皮質ステロイド投与のための経皮的方法及びパッチ
CN1146721A (zh) 通过指甲给药的全身药物输送系统
WO2011064769A1 (en) Methods and pharmaceutical compositions for the treatment of hot flashes